Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1280-5090 | Registry Identifier | ICTRP | |
| 2023-508870-27 | Registry Identifier | CTIS |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to measure the efficacy (Myeloma response) of subcutaneous (SC) isatuximab treatment in combination with carfilzomib and dexamethasone in adult participants with RRMM having received 1 to 3 prior lines of therapy, and to characterize the PK of isatuximab in combination with carfilzomib and dexamethasone after manual and On Body Delivery System (OBDS) administration. After confirmation of the feasibility of SC isatuximab by manual administration, patient will be randomized to 1 of the 2 delivery methods of SC isatuximab.
The duration of the study for a participant will include a period for screening of up to 28 days. A cycle duration is 28 days. Participants will be allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to discontinue treatment, or any other reason, as well as the study treatment is commercially available and reimbursed in the participant's country, or is available from another source, whichever is first. The overall study duration will be of approximately 45 months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1: manual administration | Experimental | Isatuximab will be administered manually for 8 minutes on Day 1 of Cycle 1 followed by 6 minutes from Day 8 of Cycle 1 and thereafter, in combination with carfilzomib and dexamethasone. Participants may receive other treatments as rescue medication or background medication. |
|
| Part 1 Cohort 2: manual administration | Experimental | Isatuximab will be administered manually for 6 minutes on Day 1 of Cycle 1 and thereafter, in combination with carfilzomib and dexamethasone. Participants may receive other treatments as rescue medication or background medication. |
|
| Part 2 Cohort 3 Randomized Cohort: OBDS to manual | Experimental | Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from OBDS to manual administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Isatuximab | Drug | Investigational medicinal product; Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall response rate (ORR) - Cohorts 1 to 3 | ORR defined as the proportion of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to the 2016 International Myeloma Working Group (IMWG) criteria assessed by Independent Review Committee (IRC). | 6 months after the Last Participant In (LPI) i.e., approximately 16 months |
| Maximum observed concentration (Cmax) over Cycle 1- Cohorts 4 to 5 | Cycle 1 (28 days) | |
| Cumulative area under the curve over the first 4 weeks (AUC4weeks) of isatuximab treatment- Cohorts 4 to 5 | Cycle 1 (28 days) |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6 | Patient preference for method of administration defined as the proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6 using the patient experience and satisfaction questionnaire version 2 (PESQ v2). | 6 months from LPI i.e., approximately 16 months |
Not provided
Inclusion Criteria:
Participants must have a documented diagnosis of multiple myeloma (MM)
Participants with measurable disease defined as at least one of the following:
Participant with relapsed and/or refractory MM with at least 1 prior line of therapy and no more than 3 prior lines of therapy.
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and either is not a female of childbearing potential (FCBP) or agrees to practice complete abstinence or use approved contraception methods.
Male participants agree to practice true abstinence or agree to use approved contraception methods while receiving study treatment, during dose interruptions and at least 5 months following study treatment discontinuation, even if has undergone a successful vasectomy.
Capable of giving signed informed consent.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Sciences & Operations | Sanofi | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Investigational Site Number : 0360002 | Wollongong | New South Wales | 2500 | Australia | ||
| Investigational Site Number : 0360001 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41455697 | Derived | Parmar G, Capra M, Seguro F, Hungria V, Dimopoulos MA, Delimpasi S, Minarik J, Spicka I, Pour L, Marques H, Esteves G, Sunami K, Yuda J, Hajek R, Mihalyova J, Soufflet C, Yu D, Benlhassan K, Koch V, Comerford E, Cordero P, Suzan F, Quach H. Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO. Blood Cancer J. 2025 Dec 27;16(1):16. doi: 10.1038/s41408-025-01436-0. |
| Label | URL |
|---|---|
| ACT17453 Plain Language Results Summary | View source |
Not provided
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Part 2 Cohort 3 Randomized Cohort: Manual to OBDS | Experimental | Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered manually from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from manual to OBDS administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication. |
|
| Part 3 Cohort 4 Randomized Cohort: OBDS to manual | Experimental | Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from OBDS to manual administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication. |
|
| Part 3 Cohort 4: Randomized Cohort: manual to OBDS | Experimental | Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered manually from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from manual to OBDS administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication. |
|
| Part 3 Cohort 5 Randomized Cohort: OBDS to manual administration in Chinese participants | Experimental | Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from OBDS to manual administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication. |
|
| Part 3 Cohort 5 Randomized Cohort: manual to OBDS administration in Chinese participants | Experimental | Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered manually from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from manual to OBDS administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication. |
|
| Carfilzomib | Drug | Investigational medicinal product; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous |
|
|
| Dexamethasone | Drug | Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Tablet; Route of administration: Oral |
|
| Dexamethasone IV | Drug | Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous |
|
| Montelukast | Drug | Background Treatment; ATC code: R03DC03; Pharmaceutical form: As per local commercial product; Route of administration: Oral |
|
| Acetaminophen | Drug | Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV) |
|
| Diphenhydramine | Drug | Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV |
|
| Methylprednisolone | Drug | Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV |
|
| Incidence rate of infusion reactions (IRs) | From the signing of the informed consent to 30 days following the last administration of any study treatment i.e., up to approximately 45 months |
| Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and changes in laboratory parameters | From the signing of the informed consent to 30 days following the last administration of any study treatment i.e., up to approximately 45 months |
| Incidence rate of injection site reactions (ISRs) | 18 months after LPI i.e., approximately 28 months |
| PK concentration: trough plasma concentration (Ctrough) | Blood samples will be collected for measurement of isatuximab concentrations. | Cycle 2 Day 1 and Cycle 6 Day 1 (1 Cycle = 28 days) |
| Overall response rate (ORR) | Proportion of participants with sCR, CR, VGPR, and PR according to the 2016 IMWG criteria assessed by investigator. | 6 months after the Last Participant In (LPI) i.e., approximately 16 months |
| Duration of response (DOR) | DOR defined as time from date of first IRC-determined response for participants achieving PR or better to first documentation of progressive disease (PD) determined by IRC or death, whichever occurred first, for Cohorts 1 to 3. For Cohorts 4-5, the time from date of first investigator determined response for participants achieving PR or better to first documentation of progressive disease (PD) determined by investigator or death, whichever occurred first. | 6 months after the Last Participant In (LPI) i.e., approximately 16 months |
| Time to first response (TT1R) | TT1R defined as time from first investigational medicinal product (IMP) administration or randomization to first IRC determined response (PR or better) that is subsequently confirmed, for Cohorts 1 to 3. For cohorts 4-5, the time from first IMP administration or randomization to first investigator determined response (PR or better) that is subsequently confirmed. | 6 months after the Last Participant In (LPI) i.e., approximately 16 months |
| Time to best response (TTBR) | TTBR defined as time from first IMP administration or randomization to first occurrence of IRC determined best response (PR or better) that is subsequently confirmed, for Cohorts 1 to 3. For cohorts 4-5, the time from first IMP administration or randomization to first occurrence of investigator determined best response (PR or better) that is subsequently confirmed. | 6 months after the Last Participant In (LPI) i.e., approximately 16 months |
| Progression free survival (PFS) | PFS defined as time from the date of first IMP administration or randomization to the date of first documentation of PD as determined by IRC for Cohorts 1 to 3 and by Investigator for all cohorts, or the date of death from any cause, whichever comes first. | 18 months after LPI i.e., approximately 28 months |
| Overall survival (OS) | OS defined as time from the date of first IMP administration or randomization to death from any cause. | 18 months after LPI i.e., approximately 28 months |
| Incidence of participants with anti-drug antibodies (ADA) against isatuximab | From Cycle 1 Day 1 to follow-up (90 days from last administration) i.e., approximately 13 months (1 Cycle = 28 days) |
| Patient Expectations Questionnaire at Baseline (PEQ-BL v2) with isatuximab administered subcutaneously | PEQ-BL v2 is a participant assessed questionnaire. It will be completed at baseline prior to study treatment administration or other study related procedures. This questionnaire has been designed to assess the expectations of the participants regarding both the treatment (side effects, worth taking) and the administration method (confidence, comfortability, pain, side effects, potential time-savings), as well as to understand previous treatment experience from the participant (experience with injection methods for oncology medication). | Baseline |
| Patient experience and satisfaction questionnaires (PESQ v2) with isatuximab administered subcutaneously | PESQ v2 is a participant assessed questionnaire. It has been designed to follow up on participant experience and satisfaction regarding the treatment (side effects, worth taking and overall satisfaction) and the administration method (confidence, comfortability, pain, side effects, potential time-savings and overall satisfaction). The PESQ v2 includes items to assess preference on subcutaneous injection method. This questionnaire has been developed using industry standard for instrument development and has been debriefed and adapted based on qualitative interviews with oncology patients. The more general treatment expectations instrument (v1) was further adapted and debriefed with patients to assess manual and OBDS subcutaneous delivery (v2). The PESQ v2 contains a total of 9 items. There are 6 items that are administered for the duration of treatment, and 3 preference items administered only after patient experience of both manual and OBDS. | 18 months after LPI i.e., approximately 28 months |
| Health state utility assessed using Health Resource Utilization and Productivity Questionnaire (HRUPQ) | Medical resource utilization and participant productivity will be collected from participants through a specific questionnaire developed by Sanofi for cohorts 1,2, 3, and 5. The data collected include number, nature (emergency or routine) and duration of hospitalizations, emergency room visits and outpatient medical encounters and employment history. | 18 months after LPI i.e., approximately 28 months |
| Health Related Quality of Life (HRQL) | HRQL is assessed for cohorts 1, 2, and 3 using the European Organization for Research and Treatment of Cancer (EORTC) myeloma module with 20 items (QLQ-MY20) and EORTC quality of life questionnaire with 30 questions (QLQ-C30); a total of 50 items. The EORTC QLQ-C30 provides a comprehensive assessment of the principal HRQL dimensions identified as relevant by cancer patients. The EORTC QLQ-MY20 is to be used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impact HRQL in participants with MM. | 18 months after LPI i.e., approximately 28 months |
| European Quality of Life Group questionnaire with 5 dimensions and 5 levels per dimension (EQ-5D-5L) | Health status is assessed for cohorts 1, 2, and 3, using the EQ-5D-5L, a standardized measure of health status that provides a simple, generic measure of health utility, and consists of 2 sections: descriptive and VAS. The descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The VAS records the respondent's self-rated health on a 20 cm vertical VAS with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. This information can be used as a quantitative measure of health as judged by the individual respondents. | 18 months after LPI i.e., approximately 28 months |
| Melbourne |
| Victoria |
| 3065 |
| Australia |
| Hospital Mae de Deus Site Number : 0760002 | Porto Alegre | Rio Grande do Sul | 90880-480 | Brazil |
| Clinica São Germano- Site Number : 0760003 | São Paulo | 04537-080 | Brazil |
| Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760001 | São Paulo | 05403-000 | Brazil |
| Investigational Site Number : 1560006 | Changsha | 410013 | China |
| Investigational Site Number : 1560002 | Guangzhou | 510060 | China |
| Investigational Site Number : 1560005 | Nanchang | 330006 | China |
| Investigational Site Number : 1560004 | Shenyang | 110004 | China |
| Investigational Site Number : 1560001 | Tianjin | 300020 | China |
| Investigational Site Number : 1560007 | Tianjin | 300060 | China |
| Investigational Site Number : 1560003 | Wuhan | 430030 | China |
| Investigational Site Number : 2030002 | Brno | 625 00 | Czechia |
| Investigational Site Number : 2030004 | Olomouc | 779 00 | Czechia |
| Investigational Site Number : 2030003 | Ostrava | 708 52 | Czechia |
| Investigational Site Number : 2030001 | Prague | 128 08 | Czechia |
| Investigational Site Number : 3000001 | Athens | 106 76 | Greece |
| Investigational Site Number : 3000002 | Athens | 115 28 | Greece |
| Investigational Site Number : 3920001 | Kashiwa | Chiba | 277-8577 | Japan |
| Investigational Site Number : 3920002 | Okayama | 701-1192 | Japan |
| Investigational Site Number : 6200001 | Braga | 4710-243 | Portugal |
| Investigational Site Number : 6200004 | Lisbon | 1400-038 | Portugal |
| Investigational Site Number : 6200005 | Lisbon | 1649-035 | Portugal |
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000599209 | isatuximab |
| C524865 | carfilzomib |
| D003907 | Dexamethasone |
| C093875 | montelukast |
| D000082 | Acetaminophen |
| D004155 | Diphenhydramine |
| D008775 | Methylprednisolone |
| ID | Term |
|---|---|
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 | Aniline Compounds |
| D000588 | Amines |
| D005021 | Ethylamines |
| D001559 | Benzhydryl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D011239 | Prednisolone |
Not provided
Not provided